Biotech | September 09, 2021
Eirion Therapeutics mandates HTL Biotechnology to be its exclusive Botulinum API manufacturer.
HTL will build, validate and operate a botulinum manufacturing facility in the US
HTL will build, validate and operate a botulinum manufacturing facility in the US
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Subscribe To Our Newsletter & Stay Updated
